Long-Term Safety of Baricitinib for RA

This integrated safety analysis with drug exposure up to 8.4 years showed baricitinib maintained a long-term safety profile similar to that already reported, with no new safety signals.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

U.S. Food & Drug Administration. Center for Drug Evaluation and Research: Approval package for Olumiant, 2 mg tablets. 2018 May 31.
Winthrop K, Takeuchi T, Burmester G, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: An updated integrated safety analysis [abstract 0202]. Arthritis Rheumatol. 2020 Oct;72(suppl 10).

Case A 46-year-old Caucasian female presented to the outpatient rheumatology clinic where she had been followed for several years. Her chief complaint was pain in her right knee, posterior right thigh and right hip that had begun gradually over the previous three weeks. Her past medical history was significant for rheumatoid arthritis (RA), obesity and…

Behçet’s disease is a chronic, relapsing and remitting vasculitis with multisystem involvement. Commonly referred to as the Silk Road disease due to its prevalence in the Asian and Mediterranean region of the traditional Silk Road, Behçet’s was first described by Hippocrates as a triad of symptoms—genital and oral ulcers with uveitis—and attributed to links with…

In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…

Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…

Rheumatology Case Report: Deep Vein Thrombosis Detected by Point-of-Care Ultrasound

Case Report Illustrates Hypercoagulability in Behçet’s Disease

Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

Related Articles